Giuseppe Banna: The prognostic value of prior TKI treatment in pretreated mRCC patients receiving nivolumab
Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post on LinkedIn about recent paper by Alessandra Damassi et al., titled “Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab” published on Taylor and Francis Online.
Authors: Alessandra Damassi, Malvina Cremante, Alessio Signori, Sara Elena Rebuzzi, Andrea Malgeri, Marilena Di Napoli, Orazio Caffo, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Veronica Prati, Marianna Tudini, Francesco Atzori, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Fabio Catalano, Veronica Murianni, Pasquale Rescigno, Giuseppe Luigi Banna, Giuseppe Fornarini, Sebastiano Buti
“Pleased to share our latest research published in Immunotherapy investigating the prognostic value of the type of prior tyrosine kinase inhibitor (TKI) treatment—specifically sunitinib versus pazopanib—in pretreated metastatic renal cell carcinoma (mRCC) patients receiving nivolumab.
Key Findings:
- No significant difference in overall response rate, disease control rate, progression-free survival, or overall survival between patients pretreated with sunitinib versus pazopanib.
- This suggests that neither TKI offers a clear advantage in priming the effectiveness of subsequent nivolumab therapy.
Conclusion:
Our results highlight the need for further research to better understand the impact of prior TKI choice on immunotherapy outcomes in mRCC patients.
For those interested in a deeper dive, you can access the full paper here.
A big thank you to all the co-authors and collaborators who contributed to this study!”
Source: Giuseppe Banna/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023